For us, drug discovery is not just business. It's personal.
When our co-founder and CEO, Ping Yeh, was diagnosed with Hodgkin’s Lymphoma, he was stunned to learn that the only way to test whether his heart would survive the drug toxicity was a post-treatment measurement. After recovery, Ping took his knowledge of nanotechnology and his skills leading cross-functional teams to solve this challenging problem in the life science industry. He now leads a cross-functional team that is upending conventional drug development and toxicity testing by enabling researchers to quickly and economically conduct high-throughput toxicity and drug development studies in ready-to-assay plates containing functional microOrgans engineered from hiPSCs.